A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline

R-Pharm

Status and phase: Completed; Phase 2

Conditions: Metastatic Breast Cancer

Treatments: Drug: Ixabepilone

Study type: Interventional

Funder types: Industry

Identifiers

NCT01027208

CA163-130

Details and patient eligibility

About

To provide extended access to Ixabepilone therapy to subjects with metastatic breast cancer who have completed the previous Phase II study (CA163-107)

Enrollment: 20 patients

Sex: Female

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women aged 20 years or older
• Patients with metastatic breast cancer whose primary lesion was definitely diagnosed to be breast by histological or cellular examination

Exclusion criteria

• Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≥2

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Ixabepilone

Experimental group

Treatment:

Drug: Ixabepilone